Replies to post #198088 on Avid Bioservices Inc (CDMO)

[md1225]

EBS with a comparative study like this you must have a theory of when we see the "value" of bavituximab start.

Immunotherapy is the future of oncology and clearly bavituximab will surpass these results with no side effects!

The price per share will reset when we all least expect it. A major move will happen like back in March in anticipation of liver results imo.